Emerging drugs for the treatment of cervical cancer.

about

Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring.

P2860

Q36206239-22B33CD5-96C6-4731-818C-894F77BE5F1B Q38892126-6A87DAA2-F027-42C5-B8F5-265D489BA1AA

P2860

Emerging drugs for the treatment of cervical cancer.

Item

http://www.wikidata.org/entity/Q38314157

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Emerging drugs for the treatment of cervical cancer.

@en

type

Item

label

Emerging drugs for the treatment of cervical cancer.

@en

prefLabel

Emerging drugs for the treatment of cervical cancer.

@en

P1476

Emerging drugs for the treatment of cervical cancer.

@en

P2093

Alberto Serrano-Olvera

http://www.w3.org/2001/XMLSchema#string

Alfonso Dueñas-González

http://www.w3.org/2001/XMLSchema#string

Jaime Coronel

http://www.w3.org/2001/XMLSchema#string

Lucely Cetina

http://www.w3.org/2001/XMLSchema#string

P2860

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

HER2 expression in cervical cancer as a potential therapeutic target

Epigenetics of cervical cancer. An overview and therapeutic perspectives

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.

Cancer statistics, 2014

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

Novel cytotoxic agents: epothilones

Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

P304

165-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2015.1002768

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25578210

http://www.w3.org/2001/XMLSchema#string

Emerging drugs for the treatment of cervical cancer.

about

P2860

P2860

Emerging drugs for the treatment of cervical cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698